183 related articles for article (PubMed ID: 22666793)
1. Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas.
Cunha LL; Morari EC; Nonogaki S; Soares FA; Vassallo J; Ward LS
Clinics (Sao Paulo); 2012; 67(5):483-8. PubMed ID: 22666793
[TBL] [Abstract][Full Text] [Related]
2. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
3. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.
Mathai AM; Kapadia MJ; Alexander J; Kernochan LE; Swanson PE; Yeh MM
Am J Surg Pathol; 2012 Jul; 36(7):980-6. PubMed ID: 22446942
[TBL] [Abstract][Full Text] [Related]
4. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.
Hua W; Yuan A; Zheng W; Li C; Cui J; Pang Z; Zhang L; Li Z; Goll R; Cui G
Pathol Res Pract; 2016 Feb; 212(2):106-12. PubMed ID: 26724144
[TBL] [Abstract][Full Text] [Related]
6. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma.
Cunha LL; Morari EC; Guihen AC; Razolli D; Gerhard R; Nonogaki S; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2012 Dec; 77(6):918-25. PubMed ID: 22738343
[TBL] [Abstract][Full Text] [Related]
7. FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment.
Ugolini C; Elisei R; Proietti A; Pelliccioni S; Lupi C; Borrelli N; Viola D; Leocata P; Vitti P; Miccoli P; Toniolo A; Basolo F
Thyroid; 2014 Feb; 24(2):339-46. PubMed ID: 23915122
[TBL] [Abstract][Full Text] [Related]
8. Expression of NCAM and OCIAD1 in well-differentiated thyroid carcinoma: correlation with the risk of distant metastasis.
Yang AH; Chen JY; Lee CH; Chen JY
J Clin Pathol; 2012 Mar; 65(3):206-12. PubMed ID: 22081784
[TBL] [Abstract][Full Text] [Related]
9. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin/α-catenin deregulated co-expression in thyroid carcinoma based on tissue microarray digital image analysis.
Tsiambas E; Ragos V; Georgakopoulos G; Rigopoulos DN; Fotiades PP; Chatziioannidis A; Stamatelopoulos A; Vilaras G; Karameris A
J BUON; 2016; 21(2):450-5. PubMed ID: 27273957
[TBL] [Abstract][Full Text] [Related]
11. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues.
Ling A; Edin S; Wikberg ML; Öberg Å; Palmqvist R
Br J Cancer; 2014 May; 110(10):2551-9. PubMed ID: 24675384
[TBL] [Abstract][Full Text] [Related]
12. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.
Cunha LL; Marcello MA; Nonogaki S; Morari EC; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2015 Aug; 83(2):246-53. PubMed ID: 25130519
[TBL] [Abstract][Full Text] [Related]
13. FOXP3 and CD25 double staining antibody cocktails identify regulatory T cells in different types of tumor tissues using tissue microarrays.
Liu X; Wang X; Ding J; Gao Y; Zhao Y; Zhao R; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Feb; 38():67-70. PubMed ID: 30502715
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E
J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146
[TBL] [Abstract][Full Text] [Related]
15. Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.
Liu Y; Yun X; Gao M; Yu Y; Li X
Clin Transl Oncol; 2015 Apr; 17(4):274-80. PubMed ID: 25387566
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of tumor-infiltrating lymphocytes in non-small cell lung carcinomas.
Mlika M; Saidi A; Mejri N; Abdennadher M; Haddouchi C; Labidi S; Khiari H; Boussen H; Hsairi M; Mezni F
Asian Cardiovasc Thorac Ann; 2022 Feb; 30(2):177-184. PubMed ID: 34558296
[TBL] [Abstract][Full Text] [Related]
17. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
[TBL] [Abstract][Full Text] [Related]
18. NDRG1 protein overexpression in malignant thyroid neoplasms.
Gerhard R; Nonogaki S; Fregnani JH; Soares FA; Nagai MA
Clinics (Sao Paulo); 2010 Jun; 65(8):757-62. PubMed ID: 20835551
[TBL] [Abstract][Full Text] [Related]
19. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
[TBL] [Abstract][Full Text] [Related]
20. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
